This article is for patients with a gastroenteropancreatic neuroendocrine tumour (GEP-NET) - a cancer that starts in the hormone-producing cells of the stomach, intestines, or pancreas. If you are currently on a somatostatin analogue (SSA) such as octreotide or lanreotide and your tumour has started growing again, you may wonder whether it's time to try something different. This article compares SSAs with lutetium Lu-177 dotatate (PRRT - peptide receptor radionuclide therapy), reviews what the clinical trial evidence shows, and explains the signs that tend to mean a switch is the right next step.
What are somatostatin analogues?
Somatostatin is a hormone the body makes naturally. It attaches to receptors on the surface of neuroendocrine tumour cells and slows them down. Somatostatin analogues are synthetic versions of this hormone. The two most common SSAs are octreotide long-acting release (LAR) and lanreotide depot. Both are given as monthly injections.
SSAs do two things. First, they reduce symptoms caused by hormones the tumour produces - diarrhoea, flushing, and abdominal cramping. Second, they can slow tumour growth in SSTR-positive GEP-NETs. The CLARINET open-label extension study showed that lanreotide depot was associated with a median progression-free survival of 30.8 months in patients with advanced enteropancreatic NETs. SSAs are well tolerated, given in an outpatient setting, and are the standard starting point for systemic therapy in GEP-NETs. SSAs are better at slowing tumours than shrinking them. Eventually, many tumours start growing again.
What is Lu-177 DOTATATE?
Lutetium Lu-177 dotatate (brand name Lutathera) is a radioligand therapy. It uses the same somatostatin receptor as an SSA - but instead of just binding and slowing the tumour cell, it delivers a targeted dose of radiation directly into it. This is the basis of theranostics: using the tumour's own receptor as a delivery address for treatment. A full explanation of the mechanism is in our guide to how Lu-177 DOTATATE works by targeting somatostatin receptors.
PRRT is given as an intravenous infusion, typically in four cycles spaced 8 weeks apart. Kidney-protecting amino acids are infused at the same time to reduce the dose absorbed by the kidneys. The FDA approved Lutathera in January 2018 for adults with SSTR-positive, unresectable, or metastatic progressive GEP-NETs.
How do Lu-177 DOTATATE and somatostatin analogues compare?
| Factor | Somatostatin Analogues (SSA) | Lu-177 DOTATATE (PRRT) |
|---|---|---|
| How it works | Binds to SSTR on tumour cells; slows hormone release and tumour growth | Binds to the same receptor, then delivers targeted radiation to kill tumour cells |
| Who qualifies | SSTR-positive GEP-NETs, any grade; standard first systemic option when surgery is not possible | SSTR-positive GEP-NETs confirmed on Ga-68 DOTATATE PET; adequate kidney and bone marrow function; typically after SSA progression |
| Trial evidence on tumour control | CLARINET extension: lanreotide associated with median PFS of 30.8 months in stable, low-grade enteropancreatic NETs | NETTER-1: median PFS not reached vs 8.4 months for high-dose octreotide alone (HR 0.21, p less than 0.001) in patients with progressive midgut NETs |
| Common side effects | Injection-site reactions; diarrhoea; risk of gallstones over time; occasional blood sugar changes | Nausea during infusion; fatigue; low blood counts; low risk of kidney or bone marrow toxicity when amino-acid protection is used |
| How it is given | Monthly deep-subcutaneous or intramuscular injection; outpatient | Four intravenous infusions, 8 weeks apart; requires a specialist nuclear medicine facility |
| Role in treatment sequence | First-line systemic therapy; continued until progression or intolerance | After SSA progression for most patients; emerging evidence supports first-line use in higher-grade (grade 2-3) tumours based on NETTER-2 |
Sources: CLARINET open-label extension - Caplin et al., Endocrine-Related Cancer 2021; NETTER-1 - Strosberg et al., New England Journal of Medicine 2017.
The key difference comes down to purpose. SSAs are used to control hormone symptoms and keep slow-growing tumours stable over an extended period. PRRT is used when the tumour is actively growing despite SSA therapy and needs treatment that can more directly reduce tumour burden. Many patients take a lower SSA dose between PRRT cycles.
What the clinical trials show
The clearest evidence on when PRRT outperforms SSA therapy alone comes from two major trials: NETTER-1 and NETTER-2.
NETTER-1: the pivotal study
The NETTER-1 phase 3 trial enrolled patients with progressive, SSTR-positive midgut NETs who were already on a standard-dose SSA but whose disease kept growing. Patients were randomly assigned to receive either lutetium Lu-177 dotatate plus low-dose octreotide, or high-dose octreotide alone.
The primary results showed a clear difference in progression-free survival. The hazard ratio for disease progression or death was 0.21 (95% CI 0.13 to 0.33; p less than 0.001). This means that patients on Lu-177 DOTATATE had roughly 79% lower risk of progression or death during the follow-up period compared to those on high-dose octreotide alone. The estimated rate of progression-free survival at 20 months was 65.2% with PRRT versus 10.8% with high-dose octreotide. The objective response rate - the share of patients whose tumour visibly shrank on imaging - was 18% with PRRT versus 3% in the control group.
The final overall survival analysis showed an 11.7-month difference in median survival favouring Lu-177 DOTATATE. This difference did not reach statistical significance, partly because a large share of patients in the control group later crossed over to receive PRRT after the trial ended.
NETTER-2: rethinking first-line treatment for higher-grade tumours
The NETTER-2 trial, reported in 2024, asked a different question: could lutetium Lu-177 dotatate be used as a first-line treatment - before the tumour had progressed on SSA therapy - in patients with higher-grade (grade 2 and grade 3) GEP-NETs? The trial enrolled 226 patients with newly diagnosed, SSTR-positive advanced GEP-NETs. Those treated with Lu-177 DOTATATE plus octreotide had a median progression-free survival of 22.8 months, compared to 8.5 months in the octreotide-alone group. As the National Cancer Institute noted, this was the first positive phase 3 trial for a radioligand therapy in a first-line setting for GEP-NETs.
NETTER-2 does not change the standard approach for grade 1 and low-grade 2 tumours, where SSAs remain the first step. But it does suggest that for patients with higher-grade disease who face a higher risk of rapid progression, starting with PRRT upfront may be worth discussing with your oncologist. For a closer look at what progression-free survival data may mean for your individual timeline, see our article on how long Lu-177 DOTATATE may keep a carcinoid tumour stable.
When should you consider switching from an SSA to Lu-177 DOTATATE?
There is no single moment that automatically triggers a switch. Your oncologist will look at several things together. Understanding the main ones can help you ask more focused questions at your next appointment.
- Documented radiological progression on your current SSA. Most clinical guidelines require imaging evidence that the tumour is growing - for example, a measurable size increase on CT or MRI according to RECIST criteria - while you are on a stable SSA dose. Your team will usually compare two scans taken a few months apart before making this determination.
- High SSTR expression on a Ga-68 DOTATATE PET scan. PRRT only works if the tumour cells express somatostatin receptors at a sufficient level. A Ga-68 DOTATATE PET-CT scan confirms this. Strong uptake on that scan is one of the key positive predictors of PRRT response.
- Adequate kidney and bone marrow function. Blood tests and a GFR measurement assess kidney health. A full blood count checks bone marrow reserve. Both need to be above certain thresholds before PRRT can start safely.
- Tumour grade and Ki-67 index. SSAs tend to work best in grade 1 and low-grade 2 tumours. If your Ki-67 index is above roughly 10-15%, or if the tumour is grade 3, your oncologist may lean toward PRRT earlier, particularly given the NETTER-2 findings.
- Symptom burden. If diarrhoea, flushing, or abdominal pain is increasing and is no longer well controlled by your current SSA dose, PRRT may offer better control of both tumour growth and symptoms.
If your tumour is still stable or growing only slowly on an SSA, continuing it is often the right choice for now. Our article on whether to start Lu-177 DOTATATE now or wait in well-differentiated NETs looks at that decision in more detail.
One practical point: SSAs need to be paused before each PRRT infusion. SSAs occupy the same somatostatin receptor that lutetium Lu-177 dotatate needs to bind to, so they can reduce the amount of therapy that reaches the tumour. Most centres ask patients to stop octreotide LAR 4 to 6 weeks before each cycle, and lanreotide depot 8 to 12 weeks before. Your treatment team will give you exact timing instructions based on your current dose.
What if PRRT is not the right step for you yet?
Not every patient with a progressing GEP-NET qualifies for PRRT. If a Ga-68 DOTATATE PET scan shows low or no receptor expression, PRRT is unlikely to work. If kidney function or blood cell counts are low, your doctor may recommend other treatments instead. Your oncologist can discuss what those options are based on your tumour type, grade, and overall health.
If you are not certain that all available pathways have been considered for your case, a second opinion from a specialist in neuroendocrine tumours and theranostics is a reasonable step. You can request a second opinion through Art of Healing Cancer on whether Lu-177 DOTATATE is right for you, and what alternatives exist if not. The team includes nuclear medicine physicians and NET specialists who can review your Ga-68 DOTATATE PET results and advise on sequencing.
Switching from monthly injections to hospital infusions can cause anxiety. Talk to your doctor or counselor if you're having trouble managing stress.
Access and cost: where is PRRT available?
Lutetium Lu-177 dotatate is available at specialist nuclear medicine centres in the United States, selected European countries, Australia, and India. In many parts of the Middle East, Africa, and South Asia it is not available locally, which leads some patients to travel for treatment. A country-by-country comparison of what PRRT costs is covered in our article on Lu-177 DOTATATE cost in India versus the US, UAE, and UK for NET patients.
If you would like to have your eligibility reviewed based on your scan results and medical history, you can submit your reports through the Lutetium Therapy contact form. If PRRT turns out not to be the right fit, the team can advise on what alternatives are appropriate for your tumour type and stage.
When to talk to your doctor
Talk to your oncologist promptly if your most recent scan shows the tumour has grown compared to your previous one, if your symptoms are becoming harder to control at your current SSA dose, or if you have been on an SSA for more than 12 months and have not yet had a Ga-68 DOTATATE PET scan. Asking specifically about PRRT eligibility - and whether a nuclear medicine or theranostics centre review is appropriate for your case - is a reasonable question to raise at your next appointment.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Can I stay on my SSA while receiving Lu-177 DOTATATE?
Generally, no - not during the active PRRT cycles. SSAs occupy the same somatostatin receptor that lutetium Lu-177 dotatate needs to bind to, so they may reduce how much of the therapy reaches the tumour. Most centres ask patients to pause octreotide LAR 4 to 6 weeks before each infusion cycle, and lanreotide depot 8 to 12 weeks before. After completing all four cycles, many patients restart an SSA as a maintenance treatment. Your treatment team will give you specific timing instructions based on which SSA you are taking and your current dose.
Does Lu-177 DOTATATE work better than octreotide or lanreotide?
They serve different purposes at different stages of disease. SSAs are very effective at controlling symptoms and stabilising slow-growing tumours as a first-line treatment. Lu-177 DOTATATE has shown significantly better progression-free survival than high-dose octreotide in patients whose tumours were already growing on SSA therapy, based on the NETTER-1 trial. The two treatments are not directly competing - PRRT is typically used after SSA therapy has stopped controlling the disease, not instead of it from the start. For patients with higher-grade tumours, the NETTER-2 trial suggests PRRT may sometimes be appropriate as an earlier treatment.
How do I know if my GEP-NET still has enough somatostatin receptors for PRRT to work?
A Ga-68 DOTATATE PET-CT scan shows whether your tumour cells still express somatostatin receptors at a level high enough for PRRT to work. The scan uses a small radioactive tracer that binds to the same receptors as lutetium Lu-177 dotatate, so it gives a direct read on how well the therapy could reach the tumour. High uptake across your lesions is a positive sign for PRRT candidacy. This scan is done before treatment is approved and sometimes repeated before a new course of PRRT is considered.
What happens if my GEP-NET starts growing again after Lu-177 DOTATATE?
Like SSAs, PRRT does not work indefinitely for every patient. If the tumour progresses after a full course of PRRT, options may include re-treatment with PRRT in carefully selected patients, other systemic therapies suited to your tumour type and grade, or clinical trials. Your oncologist will assess the pattern of progression and your overall health before recommending a next step. A repeat Ga-68 DOTATATE PET scan is usually part of that assessment.
Is Lu-177 DOTATATE available in my country?
Availability varies significantly. In the United States (brand name Lutathera), parts of Europe, Australia, and India, it is available at specialist nuclear medicine centres. In many parts of the Middle East, Africa, South Asia, and other regions it may not be offered locally, which is why some patients travel to India or Europe for treatment. Checking whether a specialist NET centre in your country offers Ga-68 DOTATATE PET imaging is a good starting point, since having that scan available is closely linked to whether PRRT can be accessed locally.
Will Lu-177 DOTATATE cure my GEP-NET?
PRRT is not described as a cure for GEP-NETs. It is associated with meaningful improvements in progression-free survival and, in the NETTER-1 trial, a clinically meaningful difference in overall survival compared to high-dose octreotide alone. For many patients, it may significantly reduce the rate of tumour growth, improve quality of life, and extend the period before the disease progresses further. Your oncologist can give you a more individualised picture based on your tumour grade, extent of disease, and scan results.